Merck & Co. announces SPR2015 license as Merck & Co. stock trades EUR 127.96
Published on 10/03/2026 at 10:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
On September 28, 2026, Merck & Co. announced an exclusive global license agreement with SciBrunch Therapeutics for SPR2015, an investigational preclinical oral KRAS G12D inhibitor, according to the company release.
Merck & Co. stock was at EUR 127.96 in weekend trading at Lang & Schwarz at 10:21 a.m. CEST on October 3, 2026. That was plus 0.02 percent versus the EUR 127.94 close at Lang & Schwarz on October 2, 2026.
Weekend trading at Lang & Schwarz
The current indication was EUR 127.96 at 10:21 a.m. CEST on October 3, 2026. The quote was EUR 0.02 above the EUR 127.94 close at Lang & Schwarz on October 2, 2026. The further course of weekend trading at Lang & Schwarz until 1:00 p.m. CEST is shown by the continuously updated real-time quote of Merck & Co. stock.
License agreement
Under the agreement, SciBrunch granted Merck exclusive worldwide rights to develop, manufacture and commercialize SPR2015. SciBrunch will receive a USD 400 million upfront payment and is eligible for milestone-related payments. The total potential aggregate value of the transaction is USD 2.13 billion, and the transaction has closed. Merck said it will record a USD 400 million pretax charge, or approximately USD 0.13 per share, in its third-quarter 2026 GAAP and non-GAAP results. These details were reported in the Merck release.
Next Xetra session
The next Xetra session is scheduled for October 5, 2026.
